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Objective: Depressive effects of cardiopulmonary bypass on cell-mediated
immune responses may lead to postoperative infectious complications. We
previously reported that cimetidine reduced postbypass depression of the
cytotoxic activity of natural killer cells. This study evaluated cimetidine as
an agent to preserve cellular immunity after cardiac operations. Methods:
In a prospective randomized study, 20 patients were divided into two groups
of equal size. Cimetidine-group patients received 400 mg of cimetidine
intravenously before bypass and a 33 mg/hr intravenous infusion of
cimetidine after the operation, continuing until the fifth postoperative day.
Control-group patients received conventional perioperative therapy. Lym-
phocyte subsets, natural killer cell activity, percentage of CD561CD161
(percentage of natural killer cells), and percentage of CD11b1CD81
(percentage of suppressor T lymphocytes) were measured perioperatively.
Results: Although temporary postoperative reductions in percentages of
CD31, CD41, and CD561CD161 cells were observed in both groups, CD81
percentages on postoperative day 1 and CD11b1CD81 percentages on
postoperative days 1 and 3 in the cimetidine group were significantly lower
compared with those in the control group (p 5 0.01, p 5 0.004, and p 5 0.02,
respectively). Temporary postoperative reduction of natural killer cell
activity was also observed in both groups, but the natural killer cell activity
on postoperative day 1 in the cimetidine group (17.1%) was significantly
higher (p 5 0.02) than that in the control group (8.20%). Conclusions:
Cimetidine counteracts depressive effects of cardiopulmonary bypass on
cell-mediated immunity and may possibly reduce postoperative suscepti-
bility to infection. (J Thorac Cardiovasc Surg 1998;116:312-8)
Patients undergoing cardiac operations with car-diopulmonary bypass (CPB) are subjected to
many kinds of postoperative insults to cellular im-
munity. CD41 (helper/inducer) lymphocyte reduc-
tion,1-9 CD81 (suppressor/cytotoxic) lymphocyte el-
evation,1-5 and reduction in natural killer (NK) cell
cytotoxic activity3, 4, 6 are seen on postoperative days
(PODs) 1 to 3, and for almost all of these, levels will
return to normal by POD 7. CD41 (helper T) cells
can help B cells make antibodies and activate the
actions of other effector cells. On the other hand,
CD81 (suppressor T) cells reduce the immune
responses of other T cells or B cells. NK cells can
activate functions of macrophages. Decreased num-
bers of B lymphocytes5, 10 and poor response to
mitogens2, 4, 7, 8 have also been reported. These de-
pressive effects of CPB on cellular immunity in-
crease the risk of infectious complications such as
septic multiorgan failure.1, 2
Cimetidine, a histamine type 2 receptor antago-
nist, has been shown to increase immunoreactivity
by activating interleukin-2 production,11, 12 inhibit-
ing suppressor T lymphocyte activity,11, 13, 14 and
enhancing NK cell activity.15 Improved immunore-
activity resulting from administration of cimetidine
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has been considered to be associated with prolonged
survival time in patients with malignant diseases16-19
and improvement in resistance to infection.20 On
the basis of these clinical studies, many physicians
have suggested the possibility of using cimetidine as
an agent of adoptive immunotherapy. We previously
reported that the perioperative use of cimetidine
preserved NK cell activity after cardiac operations
with CPB.21 The objective of this study was to
investigate the effect of cimetidine on cellular im-
munity after CPB in more detail.
Patients and methods
Twenty patients undergoing either coronary artery by-
pass grafting or heart valve operations, without evidence
of concomitant malignancy or immunologic disorder, were
included in this study. The study was approved by the
ethics review board of Yamanashi Central Hospital, Ya-
manashi, Japan, and informed consent was obtained from
each patient. In this prospective randomized trial, the
patients were divided into two groups of equal size.
Patient characteristics are summarized in Table I. All
patients received high-dose fentanyl (50 mg/kg) anesthesia
to which morphine (0.4 mg/kg) and midazolam were
added. The cimetidine group of patients received an
infusion of 400 mg of cimetidine (SmithKline Beecham,
Tokyo, Japan) intravenously over 20 minutes soon after
the induction of anesthesia and before CPB. In addition,
patients in the cimetidine group were given a 33 mg/hr
continuous intravenous infusion of cimetidine (normal
daily dose for antacid therapy) starting soon after the
operation and continuing until POD 5, when generally
suppressed cellular immunity returns to an almost normal
level. The control group of patients received conventional
perioperative therapy.
Extracorporeal perfusion was performed with use of
moderate hypothermia with a Sarns 7400MDX roller
pump, a Sarns Turbo 9443 membrane oxygenator, and a
prime of 1.5 L of standard electrolyte solution containing
sodium bicarbonate, mannitol, dextran, and heparin. All
patients received cefazolin sodium as antibiotic prophy-
laxis during (2 gm) and after (4 gm/day for 5 days) the
operation. Autologous blood transfusions were adminis-
tered if the patient tolerated blood storage before the
operation. Patients who required homologous transfusion
were excluded from the study.
Immunologic investigations. Peripheral blood samples
were taken preoperatively and on PODs 1, 3, and 7.
Peripheral blood mononuclear cells were prepared soon
after the sampling.
Flow cytometric analysis. Lymphocytes were isolated
with a Ficoll-Hypaque gradient centrifugation (Ficoll,
Pharmacia, Piscataway, N.J.; Hypaque sodium diatrizoate,
Winthrop Laboratories, New York, N.Y.) at 1500 rpm at
20° C and were washed and suspended in a balanced salt
solution. Lymphocytes were analyzed after staining with
fluorescein isothiocyanate– or phycoerythrin-conjugated
monoclonal antibodies. The following monoclonal anti-
bodies were used to detect lymphocyte subpopulations
(Becton Dickinson, Mountain View, Calif.): CD3 (mature
T cell), CD4 (helper/inducer T cell), and CD8 (suppres-
sor/cytotoxic T cell). The coexpressions of the CD11b
marker on CD8 cells and the CD56 marker on CD16 cells
were studied with the use of two-color immunofluores-
cence to detect suppressor T cells and NK cells, respec-
tively. The cells stained with antibodies were counted with
a flow cytometer (FACStar, Becton Dickinson).
NK cell cytotoxicity assay. Lymphocytes isolated with
Ficoll-Hypaque gradient (effector cells) and chromium
51–labeled K-562 cells (target cells) were mixed in an
RPMI 1640 medium at an effector to target ratio of 20:1.
After incubation in 5% carbon dioxide for 4 hours at
37° C, NK cell cytotoxicity was calculated on the basis of
the radioactivity of chromium 51, which was estimated
with use of a scintillation counter. NK cell activity was
expressed as the percentage of cytolysis according to the
following expression: percent cytolysis 5 (cpm experimen-
tal release – cpm spontaneous release)/(cpm maximum
release – cpm spontaneous release) 3 100, where cpm is
counts per minutes. The spontaneous release was the
amount of radioactivity released from target cells in the
growth medium and the maximum release was the total
radioreactivity in the target cells.
Statistical analysis. Results are presented as the mean
plus or minus the standard error of the mean. Two-way
analysis of variance with adjustment for repeated mea-
sures was used for intergroup comparison. The calculated
significant probabilities were adjusted by Dunnett’s mul-
ticomparison method to control type I errors. Analysis of
variance with the Bonferroni/Dunn multicomparison
method as a post hoc test was used for intragroup
comparison. Comparisons of the patient characteristics
and surgical data were made with the Student’s t test. All
data were computed by the MIXED procedure in SAS
software release 6.12.
Table I. Patient characteristics and surgical data
Cimetidine
group
(N 5 10)
Control
group
(N 5 10) p Value
Age (yr) 62.0 6 2.5 62.6 6 3.6 0.89
Weight (kg) 58.1 6 2.6 58.7 6 1.7 0.90
Sex
Male 8 7
Female 2 3
CABG 7 6
Valve operation 3 4
Autologous blood
transfused (ml)
480 6 112 440 6 122 0.88
CPB duration (min) 87.7 6 8.6 87.5 6 7.1 0.99
ACC duration (min) 48.0 6 6.3 46.8 6 4.8 0.88
Lowest rectal
temperature
during CPB (°C)
29.1 6 0.29 28.9 6 0.34 0.64
Values are given as the mean plus or minus the standard error of the mean.
CABG, Coronary artery bypass grafting; ACC, aortic crossclamping.
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Results
Table I shows the clinical characteristics of the
patients. There were no significant differences in
age, sex ratio, or CPB time between the two
groups. Autologous blood transfusions were per-
formed in seven patients in the cimetidine group
and six patients in the control group; there were
no significant differences in the average amount of
autologous blood transfused between the groups
(p 5 0.87). None of the patients died during
hospitalization and none had any significant post-
operative complications, with the exception of
one. One case of postoperative infection was
observed during this study, which occurred in a
63-year-old female patient in the control group
who underwent coronary artery bypass grafting.
Her early postoperative course was uneventful,
but a fever developed on POD 5. Because a large
quantity of pus was discharged from the medias-
tinal wound on POD 7, emergency reexploration
was performed. It became apparent that there was
extensive infection throughout the pericardial
space. After irrigation with a large amount of
saline solution and de´bridement of the necrotic
tissue, the chest was closed with three drainage
tubes without sternal closure. A culture of the
discharge revealed methicillin-resistant Staphylo-
coccus aureus. The mediastinitis resolved after 3
weeks of continuous saline solution irrigation via
the tubes and administration of intravenous vanco-
mycin. It is noteworthy that the NK cell activity in
this patient both before the operation and on POD
1 was extremely low (3% and 2%, respectively).
Lymphocyte subsets. The perioperative changes
of lymphocyte subsets are shown in Table II. A
temporary postoperative reduction of CD8 level was
observed in the cimetidine group. There was a
significant difference in the CD8 level on POD 1
between the groups (p 5 0.01): the cimetidine group
had a 21.2% reduction whereas the control group
had a 21.7% elevation, in comparison with the
preoperative levels. The CD4/CD8 ratio on POD 1
was decreased in both groups compared with the
preoperative level. There were significant differ-
Table II. Changes in perioperative immunologic data
Group Preop. POD 1 POD 3 POD 7
Lymphocyte count (per mm3) Cimetidine 1782 6 181 806 6 84.9 (0.0006) 1476 6 183 (0.26) 1997 6 297 (0.43)
Control 1935 6 148 822 6 71.2 (,0.0001) 1625 6 200 (0.26) 2034 6 260 (0.72)
CD3 (%) Cimetidine 62.2 6 1.37 31.8 6 3.33 (,0.0001) 55.5 6 4.33 (0.09) 66.5 6 2.14 (0.28)
Control 64.2 6 1.59 33.3 6 2.51 (,0.0001) 59.3 6 3.34 (0.22) 64.3 6 2.50 (0.98)
CD4 (%) Cimetidine 41.9 6 1.80 21.0 6 2.14 (,0.0001) 41.9 6 1.92 (0.99) 51.0 6 2.65 (0.01)
Control 44.8 6 2.82 19.3 6 2.23 (,0.0001) 37.4 6 3.18 (0.04) 48.0 6 2.83 (0.37)
CD8 (%) Cimetidine 24.7 6 1.46 19.5 6 1.79 (0.07)* 8.20 6 1.90 (0.03) 22.5 6 2.54 (0.44)
Control 23.2 6 2.28 28.2 6 2.63 (0.09)* 23.3 6 1.79 (0.98) 22.2 6 1.64 (0.73)
CD4/CD8 ratio Cimetidine 1.76 6 0.15 1.14 6 0.13 (0.06)† 2.50 6 0.24 (0.03)‡ 2.60 6 0.38 (0.01)
Control 2.15 6 0.27 0.76 6 0.12 (,0.0001)† 1.67 6 0.17 (0.15)‡ 2.31 6 0.26 (0.61)
CD11b1CD81 (%) Cimetidine 10.8 6 1.41 7.40 6 1.05 (0.10)§ 5.60 6 0.59 (0.01)\ 10.3 6 0.67 (0.78)
Control 9.40 6 1.78 15.7 6 2.80 (0.003)§ 9.70 6 1.15 (0.88)\ 9.52 6 0.52 (0.95)
CD11b1CD81 cell count Cimetidine 186 6 32.9 57.4 6 8.42 (0.001)¶ 80.6 6 12.4 (0.007)# 210 6 40.8 (0.53)
(per mm3) Control 175 6 28.8 131 6 28.6 (0.26)¶ 157 6 24.5 (0.65)# 192 6 24.2 (0.66)
CD561CD161 (%) Cimetidine 14.4 6 2.08 27.5 6 4.22 (0.0001) 7.77 6 0.49 (0.03) 7.60 6 1.32 (0.03)
Control 14.5 6 2.35 19.2 6 2.01 (0.12) 6.88 6 0.94 (0.01) 8.22 6 1.08 (0.04)
CD561CD161 cell count Cimetidine 254 6 52.5 207 6 28.6 (0.37) 115 6 7.10 (0.01) 159 6 41.5 (0.07)
(per mm3) Control 284 6 52.7 161 6 23.0 (0.02) 111 6 21.6 (0.001) 173 6 38.6 (0.04)
NK cell activity (%) Cimetidine 36.8 6 3.58 17.1 6 1.50 (,0.0001)** 19.3 6 2.11 (0.0005) 36.7 6 3.34 (0.98)
Control 37.8 6 5.99 8.20 6 2.03 (,0.0001)** 15.9 6 1.99 (,0.0001) 34.3 6 3.96 (0.46)
Values are given as the mean plus or minus the standard error of the mean. Data of the lymphocyte subsets are given as the percentage of the peripheral
blood mononuclear cells. p Values in parentheses are for comparisons with preoperative data. All statistically significant values with intergroup comparisons
are footnoted.
*p 5 0.01.
†p 5 0.04.
‡p 5 0.03.
§p 5 0.004.
\p 5 0.02.
¶p 5 0.02.
#p 5 0.02.
**p 5 0.02.
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ences in the ratio between the groups on POD 1
(p 5 0.04) and POD 3 (p 5 0.03).
Two-color analysis. In the control group, the
percentage of CD11b1CD81 lymphocytes (suppres-
sor T lymphocytes) on POD 1 was significantly
elevated compared with the preoperative level (p 5
0.003). The percentage in the cimetidine group was
significantly decreased on POD 1 (p 5 0.04) and
POD 3 (p 5 0.01) compared with the preoperative
level. Intergroup comparisons showed significant
differences in the percentage of CD11b1CD81 lym-
phocytes on POD 1 (p 5 0.004) and POD 3 (p 5
0.02) (Fig. 1, a).
The percentages of CD561CD161 lymphocytes
(NK cells) were elevated on POD 1 (cimetidine
group, p 5 0.0001; control group, not significant)
and then significantly reduced in the period between
POD 3 and POD 7 in both groups. There were no
significant differences in the percentages of
CD561CD161 lymphocytes between the groups
(Fig. 2, a).
NK cell cytotoxicity assay. A temporary, postop-
erative reduction of the NK cell activity was ob-
served in both groups. The NK cell activity on POD
1 in the cimetidine group (17.1% 6 1.50%) was
significantly higher (p 5 0.02) than that in the
control group (8.20% 6 2.03%) (Fig. 3).
Discussion
This clinical study has demonstrated that cell-
mediated immunity is impaired after cardiac opera-
tions involving CPB: CD31 cell count, CD41 cell
count, CD561CD161 cell count, and NK cell activ-
ity were reduced, whereas CD81 cell count and
CD11b1CD81 cell count were increased postoper-
atively. Many kinds of alterations to cellular immu-
nity have been previously identified in patients
undergoing cardiac operations with CPB. Lympho-
cytopenia, caused mainly by a reduction of the
helper/inducer (CD41) lymphocyte occurred on
POD 1 and lasted for several days after the opera-
tion, with values returning to the preoperative level
on POD 7.1, 2, 4-8 There has been some controversy
about the postoperative changes in the suppressor/
cytotoxic (CD81) lymphocyte count1-9; however,
most investigators have reported that the CD41/
CD81 ratio was reduced postoperatively.2, 3, 5, 6, 8 In
addition, NK cell activity3, 4, 6, 21 and interleukin-2
production1, 2, 8 were found to be depressed after
CPB. In vitro studies of the lymphocyte response to
concanavalin A7 or phytohemagglutinin,2, 4, 7, 8 as
well as an in vivo study of delayed-type hypersensi-
tivity to antigens,1 also demonstrated impaired re-
sponses after CPB.
To our knowledge, this is the first study that has
reported changes in the post-CPB functional subset
of suppressor T lymphocytes and NK cells with use
of a two-color analysis simultaneously with NK cell
activity analysis. When functional subsets of lym-
phocytes are stained with a single monoclonal anti-
body, it is difficult to identify specific functional
types of lymphocytes. With a two-color analysis, we
Fig. 1. Changes in (a) the percentage of suppressor T lymphocytes (CD11b1CD81 cell) in peripheral
blood and (b) their absolute count before and after CPB. Asterisks and pound signs show values that were
significantly different in intergroup comparison. *p 5 0.004; #p 5 0.02; **p 5 0.02; ##p 5 0.02.
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were able to more accurately ascertain the counts of
suppressor T lymphocytes and NK cells than can be
done with a single-color analysis.
Cell-mediated immunity is considered to be im-
portant for the prophylaxis of postoperative infec-
tions.1, 2, 3, 20 Postoperative complications such as
septic shock or mediastinitis usually occur as a result
of bacterial infection. To counteract microorgan-
isms, phagocytic cells such as monocytes, macro-
phages, and polymorphonuclear neutrophils play an
important role. Cytokines released by T cells acti-
vate these phagocytes to destroy the materials they
have internalized.22 Therefore impairment of cellu-
lar immunity after CPB may lead to infectious
complications. In fact, from a clinical perspective,
Markewitz and associates1 have reported that im-
paired immunoreactivity increases the risk of septic
multiorgan failure after cardiac operations involving
CPB.
Meanwhile, cimetidine, a histamine type 2 receptor
antagonist, has been known to enhance cell-mediated
immune responses in vivo and in vitro.11-21, 23
Several reports have demonstrated the effectiveness
of cimetidine in the treatment of various malignan-
cies unresponsive to customary treatments, includ-
ing remarkable regression of malignant melanoma24
and improved survival in patients with gastric
cancer18, 19 and colorectal cancer.16, 17 In addition, it
has been reported that administration of cimetidine
improved survival after sepsis in burned mice.20 In
consideration of these reports, we previously inves-
tigated the immunomodulating effects of cimetidine
on post-CPB cellular immunity, especially in rela-
tion to NK cell activity, and we revealed that cime-
tidine preserved NK cell activity after cardiac oper-
ations.21
With the perioperative use of cimetidine in our
latest study, the NK cell activity on POD 1 was again
shown to have been significantly preserved. Organ-
isms such as bacteria and viruses that succeed in
entering tissues are rapidly exposed to phagocytic
cells, principally polymorphonuclear leukocytes and
macrophages. It has been realized in recent years
Fig. 2. Changes in (a) the percentage of NK cells (CD561CD161 cell) in peripheral blood and (b) their
absolute count before and after CPB. There were no significant differences in intergroup comparison (p .
0.05).
Fig. 3. NK cell cytotoxic activity before operation and on
various days after CPB. Asterisks indicate statistical differ-
ences in intergroup comparison (p 5 0.02).
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that macrophages perform many of their effects via
secreted molecules, several of which show antimi-
crobial activity. Through these cytotoxic secretory
molecules, macrophages can destroy Gram-positive
bacteria. Meanwhile, in T cell–independent defense
mechanisms, NK cells release interferon-g, which
augments the microbicidal potentials of macro-
phages and increases their adherence to endothelial
cells.25 Accordingly, we consider that the immuno-
modulatory effects of cimetidine on NK cell activity
after CPB have clinical importance.
The correlation between net NK cell count
(CD561CD161 cell) and NK cell activity after car-
diac operations with CPB was revealed in this study
with the use of a two-color analysis. Nguyen and
colleagues3, 26 stated in their reports that post-CPB
reduction of NK cell activity was a result of a
decrease in the number of NK cells whose cytotoxic
function remained intact. However, our data dem-
onstrate that there are some discrepancies in the
post-CPB change between NK cell activity and NK
cell count (Fig. 2, b, and Fig. 3): NK cell activity was
lowest on POD 1, whereas NK cell count was lowest
on POD 3. In addition, from a morphologic perspec-
tive, De Angeli and colleagues7 clarified with scan-
ning electronic microscopy that lymphocytes drasti-
cally lose their microvilli on the surface during CPB,
and that microspheres connected to lymphocyte
membranes were considerably reduced. Such a lym-
phocyte may lose its cytotoxic ability. These data
suggest that NK cell cytotoxic activity may deterio-
rate after CPB. Because cimetidine did not affect
the post-CPB NK cell count, we consider that
cimetidine may have preserved the cytotoxic ability
of the NK cells.
Another important finding of the present study is
that post-CPB suppressor T cell activation was
inhibited by cimetidine (Fig. 1). It has been previ-
ously reported that cimetidine inhibits the function
of suppressor T lymphocytes.13, 14 This subset of
lymphocytes regulates the immune responses of
helper T lymphocytes, which play a central role in
cell-mediated immunity. The helper T lymphocyte
modulates various types of cellular cooperation and
produces a wide variety of cytokines. Inhibition of
suppressor T lymphocytes with cimetidine, there-
fore, may be beneficial to patients because it may
preserve the cell-mediated immune response after
CPB.
It is well known that suppressor T lymphocytes
have a receptor for histamine, which has inhibitory
effects on cellular immunity.27 It has been reported
that these suppressive effects of histamine are me-
diated through the histamine type 2 receptor.23
Therefore histamine type 2 receptor antagonists
may have an immunomodulatory effect. Hahm and
coworkers15 demonstrated that cimetidine had the
strongest immunomodulative effect compared with
that of other histamine type 2 receptor antagonists
that have a much stronger antihistaminic potency. In
consideration of these findings, it remains unclear
whether the effect of cimetidine in preserving NK
cell activity is a result of the impairment of suppres-
sor T lymphocytes or other unknown mechanisms,
which may be related to the structural features of
cimetidine.
In summary, we have demonstrated that patients
undergoing cardiac operations exhibited an alter-
ation in the peripheral lymphocyte subsets: the
percentages of CD31 cells and CD41 cells were
decreased and those of CD81 cells were increased.
There was no significant alteration in the
CD11b1CD81 cell count (net suppressor T cell
count). We also demonstrated that NK cell cytotoxic
activity and its net count (CD561CD161 cell count)
were decreased after CPB. With the perioperative
administration of cimetidine, post-CPB deteriora-
tion of NK cell activity was diminished and the
suppressor T lymphocyte count was reduced. Al-
though the number of patients included in this study
was too small to permit evaluation of the clinical
effectiveness of cimetidine, our study raises the
possibility that perioperative administration of ci-
metidine preserves cell-mediated immunity and pre-
vents infectious complications associated with car-
diac operations.
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